 |
| T-cell Lymphoma Market |
The global T-cell Lymphoma Market is estimated to be valued at US$ 1961.64 Mn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
T-cell Lymphoma refers to a type of blood cancer that develops from mature
white blood cells called T lymphocytes. The diseases affecting T-cells include
mycosis fungoides and anaplastic large cell lymphoma. T-cell Lymphoma
treatments available in the market help patients fight the disease with
targeted therapies like monoclonal antibodies, immunotherapy and precision
medicines.
Market key trends:
One of the key trends fueling the growth of T-cell Lymphoma market is
increasing adoption of advanced therapies like genetically engineered T-cells.
Genetically engineered T-cells involve modifying a patient’s own T-cells to
recognize and attack cancer cells through gene therapy techniques. These cells
are extracted from the patient's blood and modified in the laboratory to
express a gene that programs the T-cells to target specific proteins on the
patient's cancer cells. Once reinfused into the patient's bloodstream, the modified
T-cells work to find and destroy cancer cells expression the target protein.
The treatment provides more targeted and personalized approach for T-cell
Lymphoma patients.
Segment Analysis
The global T-cell lymphoma market is segmented on the basis of type and
therapy. Based on type, the market is segmented into peripheral T-cell
lymphoma, cutaneous T-cell lymphoma, and anaplastic large cell lymphoma. The
peripheral T-cell lymphoma segment dominates the market owing to increasing
prevalence rates. Based on therapy, the market is categorized into
chemotherapy, targeted therapy, immunotherapy, and bone marrow transplant. The
chemotherapy segment accounts for the largest market share due to high adoption
rates and cost-effectiveness.
Key Takeaways
Market size
The global T-Cell
Lymphoma Market Share is expected to witness high growth, exhibiting
CAGR of 9.8% over the forecast period, due to increasing incidence of lymphoma.
Regional analysis
North America dominates the global T-cell lymphoma market owing to growing
cases and increasing healthcare expenditure. Asia Pacific is expected to
witness the fastest growth over the forecast period due to rapidly improving
healthcare infrastructure and rising medical tourism.
Key players
Key players operating in the T-cell lymphoma market are F. Hoffmann-La Roche
Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin
Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson
Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG,
SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health
Companies Inc.
Read More,
https://www.insightprobing.com/t-cell-lymphoma-market-trends-size-and-share-analysis/
0 Comments